Bosch Health Campus Logo Bosch Health Campus Logo
Home
Team
Werner Schroth
Research Group Leader Breast Cancer Recurrence and Clinical Translation

Dr. Werner Schroth


Tel +49-711-8101 5647

Major Projects

  • Pharmacogenomics of breast cancer
  • Trial exploration for novel treatment predictors in hormone-sensitive breast cancer
  • Stratified endocrine therapies: supplementation of tamoxifen with endoxifen
  • Estrogen receptor regulation and signaling
  • Multiplex spatial imaging analysis of tumors
  • Computational pathology
  • Liquid biopsy in adjuvant settings
  • PIK3CA & TP53 biomarker research

Selected References

Maier, S., Schroth, W., et al. & Lukowski, R. Tamoxifen metabolites acting via BKCa orchestrate the dynamics of K+ and Ca2+ in breast cancer cells. J. Biol. Chem 302(2):111015 (2026)
Mürdter, T. E., Schroth, W., et al. & Schwab, M. Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial. Clin. Cancer Res 31, 4903–4911 (2025)
Khor, C. C. et al. Cross‐Ancestry Genome‐Wide Association Study Defines the Extended CYP2D6 Locus as the Principal Genetic Determinant of Endoxifen Plasma Concentrations. Clin Pharmacol Ther 113, 712–723 (2023)
Schroth, W. et al. Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor–Positive Breast Cancer Patients. Clin Cancer Res 26, 6523–6534 (2020)
Brauch, H., Schroth, W., Mürdter, T. & Schwab, M. Tamoxifen Pharmacogenetics and Metabolism: The Same Is Not the Same. J Clin Oncol 37, 1981–1982 (2019)

Major Networks and Collaborations, Funding

  • International Tamoxifen Pharmcogenomics Consortium (ITPC)
  • CYP2D6 Endoxifen Percentage Activity Model (CEPAM) Consortium
  • Marie Curie Initial Training Network (ITN) „FightingDrugFailure: Priorities and Standards in Phamacogenomic Research: Opportunities for a Safer and More Efficient Pharmacotherapy“
  • Funded by German Research Council (DFG), German Federal Ministry of Education and Research (BMBF), Interfaculty Center for Pharmacogenomics and Drug Research (ICEPHA), Tübingen, Germany, and Wilhelm-Sander Stiftung

Curriculum Vitae

Education and Professional Career

Since 2021

Group leader “Breast cancer” at Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology

Since 2004

Scientist in oncology research ‘pharmacogenomics and molecular profiling of breast cancer’, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Prof. H. Brauch, IKP Stuttgart, Germany

2000-2003

Consultant & scientist-in-charge ‘autoimmune diagnostics’, Dermatological Institute, Prof P. Kind, Offenbach, Germany

2001-2003

Post-doctoral position, ‘evolution of homeobox genes in lower metazoans’, Prof B. Schierwater, ITZ Hannover, Germany

2000

PhD degree at J.W.Goethe University, Frankfurt, Germany: speciation and environmental monitoring in moon jellyfish

1999-2000

Research Fellowship Deutsche Bundesstiftung Umwelt DBU

1997-2000

Dissertation at J.W.Goethe University, Frankfurt, Germany

1996-1998

Employment DFG project ‘microsatellites paternity analyses’, J.W.Goethe University

1996

Environmental Research Award, J.W.Goethe University

1995

Diploma in Biology at J.W.Goethe University, Frankfurt, Germany: population genetics in sea turtles

1987-1994

Study of Biology, J.W.Goethe University, Frankfurt, Germany

Professional Memberships

  • Affiliate membership: American Association for Cancer Research AACR

Research Group

Breast Cancer Recurrence and Clinical Translation

> Core Facility Molecular Analytics